alnylam
A Director of Peptide & Peptide-Oligonucleotide Conjugate (POC) Process Development leads technical development, scale-up, and external manufacturing of peptide and POC active pharmaceutical ingredients. The role involves advancing robust, scalable, and regulatory-ready processes from development through clinical and commercial supply.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
11% above the average for this role
Principal Research Scientist I, Peptide Chemistry
AbbVie
Business Development Representative – Oligonucleotide and Peptide CDMO
WuXi AppTec
Associate Principal Scientist – Peptide Development Chemistry - Pharmaceutical Sciences (PS)
AstraZeneca
Sr, Consultant
Syner-G
Delivery Manager – API (Process R&D)
drreddyslaboratorieslimited.com
Senior/ Principal Scientist - Peptide pharmaceutical development
Roche